Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.58 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.32 |
| ▸ | CHRNG | P07510 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL419490 | 0.84 | CYP3A4 (0.63) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL58809 | 0.81 | CYP3A4 (0.70) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL11517806 | 0.81 | MAPK1 (0.52) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL2886976 | 0.80 | P2RY6 (0.41) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL3421735 | 0.80 | CYP3A4 (0.58) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL667517 | 0.79 | CYP3A4 (0.62) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL29373346 | 0.78 | CYP3A4 (0.71) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL77895 | 0.78 | CYP3A4 (0.71) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL29870840 | 0.78 | CYP3A4 (0.60) | CYP3A4TRPA1TDP1MAPK1TSHR | |
| SCHEMBL1169221 | 0.78 | CYP3A4 (0.60) | CYP3A4TRPA1TDP1MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1481369-A | Substituted phenyluracils compound | �ݶ�ũ�����ѧ�ɷݹ�˾ | 2004-03-10 | — | — | CN | claimed |
| EP-1330443-A1 | SUBSTITUTED PHENYLURACILS | Bayer CropScience AG (DE) | 2003-07-30 | — | — | EP | claimed |
| WO-2002034725-A1 | SUBSTITUTED PHENYLURACILS | BAYER CROPSCIENCE AG (DE) | 2002-05-02 | — | — | WO | claimed |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2025-06-24 | — | — | US | disclosed |
| US-20240287020-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2024-08-29 | — | — | US | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240154124-A1 | NEGATIVE ELECTRODE PLATE AND LITHIUM-ION BATTERY COMPRISING SAME | ZHUHAI COSMX BATTERY CO., LTD. (CN) | 2024-05-09 | — | — | US | disclosed |
| US-11970474-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2024-04-30 | — | — | US | disclosed |
| CN-112074511-B | Substituted benzodiazoles and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2024-04-26 | — | — | CN | disclosed |
| EP-4313047-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | Monte Rosa Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-113851656-B | Negative electrode piece and lithium ion battery comprising same | 珠海冠宇电池股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-12-04 | — | — | US | disclosed |
| WO-2003080625-A1 | THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-10-02 | — | — | WO | disclosed |
| EP-1330443-A1 | SUBSTITUTED PHENYLURACILS | Bayer CropScience AG (DE) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002034725-A1 | SUBSTITUTED PHENYLURACILS | BAYER CROPSCIENCE AG (DE) | 2002-05-02 | — | — | WO | disclosed |
| EP-0975593-A1 | INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998050346-A2 | ACETAMIDE AND UREA DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998050358-A1 | INDOLE DERIVATIVES HAVING COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998047868-A1 | HETEROCYCLE-CONTAINING UREA DERIVATIVES AS 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | CYP3A4 2280/4885TRPA1 4132/4885TDP1 613/4885 |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | CYP3A4 2280/4885TRPA1 4132/4885TDP1 613/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | CYP3A4 3128/4885TRPA1 4870/4885TDP1 1868/4885 |
| US-11970474-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP4X1, CYP11B2 | CYP3A4 6/4885TRPA1 2677/4885TDP1 1837/4885 |
| US-20240287020-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | XDH, CYP11B2, CYP4X1 | CYP3A4 10/4885TRPA1 2277/4885TDP1 1726/4885 |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP11B2, CYP4X1 | CYP3A4 10/4885TRPA1 2277/4885TDP1 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.